Synthetic DNA Fidelity Thought Leadership

The Plasmid Bottleneck Is Not New. It Is Just Finally Solvable.

Kate E. Broderick Ph.D

August 28, 2026

For as long as nucleic acid medicine has existed, developers have structured their programs around a bottleneck that everyone in...

Read more →

GMP Manufaturing Synthetic DNA Pandemic Preparedness

Engineering the Next Era of Medicine: Manufacturing Readiness as a Competitive Advantage

Artis BioSolutions

August 26, 2026

Kate Broderick, PhD, Chief Scientific and Innovation Officer at Artis BioSolutions, joined a TechCon panel on what the next era...

Read more →

CDMO

From Evaluation to Decision: A Practical Framework for Choosing the Right CDMO

Artis BioSolutions

August 12, 2026

Over the four posts in this series, we have built a complete framework for evaluating a CDMO for advanced therapy development. We...

Read more →

CDMO CQA

Partnership Model and the Questions That Reveal the Most: How to Tell Whether a CDMO is Actually the Right Fit

Landmark Bio Team

July 20, 2026

In the first three posts in this series, we covered the manufacturing landscape for advanced therapies, the importance of...

Read more →

CDMO

Process Philosophy, Materials Strategy, and Facility Readiness: The Operational Foundations of a Strong CDMO Partnership

Landmark Bio Team

July 14, 2026

In the previous post, we covered the two structural criteria that most reliably distinguish a translational development partner...

Read more →

CMC in Advanced Therapies CDMO

Modality Expertise and Development Integration: Why Direct Experience with Your Biology Matters Most

Landmark Bio Team

July 06, 2026

In the first post in this series, we looked at the manufacturing landscape for advanced therapies and what the FDA data tells us...

Read more →

Synthetic DNA AAV

One Roof, Two Capabilities: Why Synthetic DNA + AAV Manufacturing Belongs Together

Landmark Bio Team

June 18, 2026

AAV is one of the most widely used delivery platforms in gene therapy, supporting approved treatments for inherited retinal...

Read more →

Viral Vectors CAR-T

From Bespoke to Off-the-Shelf: The Manufacturing Reckoning Behind CAR-T’s Hottest Race

Amalia Soenens & Lindsey Wolf

May 28, 2026

Last November we published POSTmark CAR-T: Delivering Therapies Without Delay, arguing that manufacturing continuity—not...

Read more →

GMP CDMO CQA

Tech-Transfer and Manufacturing for Scaling Biotech

Landmark Bio Team

April 27, 2026

At Advanced Therapies Week 2026, our Chief Technology Officer, Gregg Nyberg, joined a panel of industry leaders to discuss how...

Read more →

Artis Insights

Personalized Cancer Vaccines: The Science Is Ready. Is the Manufacturing?

The Plasmid Bottleneck Is Not New. It Is Just Finally Solvable.

Engineering the Next Era of Medicine: Manufacturing Readiness as a Competitive Advantage

From Evaluation to Decision: A Practical Framework for Choosing the Right CDMO

Partnership Model and the Questions That Reveal the Most: How to Tell Whether a CDMO is Actually the Right Fit

Process Philosophy, Materials Strategy, and Facility Readiness: The Operational Foundations of a Strong CDMO Partnership

Modality Expertise and Development Integration: Why Direct Experience with Your Biology Matters Most

One Roof, Two Capabilities: Why Synthetic DNA + AAV Manufacturing Belongs Together

From Bespoke to Off-the-Shelf: The Manufacturing Reckoning Behind CAR-T’s Hottest Race

Tech-Transfer and Manufacturing for Scaling Biotech